Table 1.
Demographic and clinical characteristics, treatment and CGI outcomes of the patients (N = 650).
| Characteristic | n (%) |
|---|---|
| Age, years, mean ± SD | 13.23 ± 3.18 |
| Age group | |
| 4–10 years | 135 (20.8) |
| 11–14 years | 230 (35.4) |
| 15–17 years | 285 (43.8) |
| Sex | |
| Female | 383 (58.9) |
| Male | 267 (41.1) |
| Psychiatric comorbidity | |
| Yes | 467 (71.8) |
| No | 183 (28.2) |
| Physical comorbidity | |
| Yes | 38 (5.8) |
| No | 612 (94.2) |
| Labelling status of current antidepressant regimen (FDA) | |
| On-label | 164 (25.2) |
| Off-label | 486 (74.8) |
| Labelling status of first antidepressant (FDA) | |
| On-label | 179 (27.5) |
| Off-label | 471 (72.5) |
| Labelling status of second antidepressant (FDA), n = 87 | |
| On-label | 19 (21.8) |
| Off-label | 68 (78.2) |
| CGI-Severity at treatment initiation | |
| Mildly ill (3) | 29 (4.5) |
| Moderately ill (4) | 424 (65.2) |
| Markedly ill (5) | 197 (30.3) |
| CGI-Improvement at last recorded follow-up | |
| Positive response (score 1–2) | 550 (84.6) |
| Very much improved (1) | 311 (47.8) |
| Much improved (2) | 239 (36.8) |
| Partial response: minimally improved (3) | 100 (15.4) |
| Concomitant psychotropic treatment | |
| No (monotherapy) | 365 (56.2) |
| Yes | 285 (43.8) |
| Any adverse effect | |
| Yes | 139 (21.4) |
| No | 511 (78.6) |
| Prior antidepressant trial | |
| Yes | 88 (13.5) |
| No | 562 (86.5) |
| Reason for discontinuation of prior antidepressant, n = 88 | |
| Lack of efficacy | 63 (71.6) |
| Partial efficacy | 10 (11.4) |
| Adverse effects | 15 (17.0) |
Percentages are calculated with N = 650 as the denominator unless another denominator (n) is stated. CGI, Clinical Global Impression; FDA, U.S. Food and Drug Administration; SD, standard deviation. Labelling status was classified according to FDA paediatric labelling (drug, indication and age). Prior antidepressant trial: discontinuation of an earlier antidepressant followed by a switch to another agent (the discontinued agent was an SSRI in 84 of 88 patients).